Regulators Say Bayer Drug Unproven as Stroke Preventer

by Kathy Jones on  September 8, 2011 at 6:28 PM Drug News
RSS Email Print This Page Comment
Xarelto, a Bayer-made drug approved in July for preventing blood clots, is so far unproven for a new proposed use as a stroke preventer, US regulators have said.
 Regulators Say Bayer Drug Unproven as Stroke Preventer
Regulators Say Bayer Drug Unproven as Stroke Preventer
Advertisement

"There is a lack of substantial evidence that rivaroxaban will have its desired effect when used as recommended in labeling," said documents released by the US Food and Drug Administration.

Advertisement
An advisory committee to the FDA would further discuss the latest findings on Thursday.

"This review posted today has to do with the application for the new use and at this point does not impact the already-approved use," said FDA spokeswoman Sandy Walsh.

Xarelto is currently on the market to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery.

Bayer's stock plunged nearly 12 percent by midday in US trading.

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Bell´s Palsy Diet Lifestyle and Heart Disease Mitral Valve Stenosis And Mitral Valve Replacement Congenital Heart Disease Signature Drug Toxicity Stress and the Gender Divide Stroke Facts Stroke Hyperventilation 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive